SuperworthCue Biopharma market cap CUE
Share price times shares outstanding: what the whole company sells for, since 2018.
- Today, Oct 23, 2026
- $135.6M
- Highest close in our data
- $855.6M
- May 2020
Cue Biopharma is worth $135.6M at the close on Oct 23, 2026, at $18.66 a share.
That is up 125% over the last year and down 65% over five years.
Its highest close in our data was $855.6M in May 2020.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $135.6M | $17.6M | $269.1M | +430% |
| 2025 | $25.6M | $21.1M | $95.7M | −61% |
| 2024 | $65.9M | $25.5M | $134.9M | −45% |
| 2023 | $119.1M | $80.5M | $211.1M | +18% |
| 2022 | $100.8M | $78.9M | $334.8M | −72% |
| 2021 | $359.2M | $318.5M | $526M | −5% |
| 2020 | $378.8M | $324.8M | $855.6M | −6% |
| 2019 | $401.7M | $104.9M | $401.7M | +330% |
| 2018 | $93.4M | $92.8M | $289.9M | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest Cue Biopharma's size, closest first, today.
| Company | Market cap |
|---|---|
| CUECue Biopharma | $135.6M |
| NATRNatures Sunshine Products | $213.8M |
| LFVNLifevantage | $73.4M |
| SPROSpero Therapeutics | $64.6M |
| ATNMActinium Pharmaceuticals | $47.8M |
| ARVNArvinas | $477.3M |
| PBYIPuma Biotechnology | $568.9M |
| IRWDIronwood Pharmaceuticals | $571.7M |
| ZVRAZevra Therapeutics | $582.6M |
| CRMDCorMedix | $611.9M |
| COLLCollegium Pharmaceutical | $747.5M |
| Peer median | $523.1M |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on Cue Biopharma
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.